New combo pill could help diabetics on insulin

NCT ID NCT02220920

Completed Disease control Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether adding canagliflozin, a diabetes pill, to insulin therapy helps people with type 2 diabetes control their blood sugar better. 146 adults took either canagliflozin or a placebo for 16 weeks while continuing their insulin. Researchers measured changes in blood sugar levels, weight, and safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Canagliflozin (a drug that helps lower blood sugar by making the kidneys remove extra sugar through urine)
What this could lead to: If successful, this could show that adding canagliflozin to insulin helps people with type 2 diabetes better control their blood sugar and possibly lose weight.
What could go wrong: This is a small, short-term (16-week) study, so results may not apply to long-term use. There is a risk of hypoglycemia (low blood sugar) when combining with insulin.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Insulin Resistance type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES MELLITUS

Contacts and locations

Locations

Reserch site

Chugoku, Japan
Reserch site

Chūbu, Japan
Reserch site

Hokkaido, Japan
Reserch site

Kanto, Japan
Reserch site

Kinki, Japan
Reserch site

Kyushu, Japan
Reserch site

Tōhoku, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.